Protective effect of protein kinase C inhibitor Ro-31-8425 on hyperpermeability of human umbilical vein endothelial cells exposed to high glucose in vitro.
- Author:
Mengchen ZOU
1
;
Yaoming XUE
Author Information
- Publication Type:Journal Article
- MeSH: Capillary Permeability; drug effects; Cells, Cultured; Endothelium, Vascular; drug effects; metabolism; Glucose; adverse effects; Human Umbilical Vein Endothelial Cells; drug effects; Humans; Indoles; pharmacology; Maleimides; pharmacology; Protein Kinase C; antagonists & inhibitors
- From: Journal of Southern Medical University 2012;32(12):1787-1791
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of different concentrations of glucose on the permeability of human umbilical vein endothelial cell monolayer and the protective effect of protein kinase C (PKC) inhibitor Ro-31-8425 against high-glucose exposure.
METHODSCultured human umbilical vein endothelial cell line EA.hy926 cells were exposed to 5.5 mmol/L glucose (control) and high-concentration glucose (10, 15, 20, 25.5, and 30 mmol/L), and the endothelial monolayer permeability was assessed by measuring the flux of FITC-labeled dextran (FITC-DΧ) across the endothelial cells. The cultured EA.hy926 cells were treated with 5.5 mmol/L glucose +saline, high glucose (25.5 mmol/L) +saline, or high glucose (25.5 mmol/L) +Ro-31-8425(10 µmol/L), and the level of PKC phosphorylation and endothelial monolayer permeability were evaluated.
RESULTSHigh glucose dose-dependently increased the permeability of the endothelial cell monolayer (P<0.01), and glucose at 25.5 mmol/L significantly increased the phosphorylation level of PKCα and PKCβ II in the cells (P<0.01). Treatment with 10 µmol/L Ro-31-8425 obviously attenuated high-glucose-induced PKCα and PKCβ II phosphorylation (P<0.01) as well as the increase of the cell monolayer permeability (P<0.01).
CONCLUSIONSHigh glucose increases the hyperpermeability of human umbilical vein endothelial cell monolayer mediated by the phosphorylation of PKC, and the PKC inhibitor Ro-31-8425 can reverse such effects.